Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study)

Woo, Young Sup; McIntyre, Roger S.; Kim, Jung Bum; Lee, Min-Soo; Kim, Jae Min; Yim, Hyeon Woo; Jun, Tae-Won

doi:10.1016/j.jad.2016.06.018

Cited by 18 publications

(11 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association is bidirectional, with depression predicting MetSyn and vice versa (Pan 2012). Recent inquiries into treatment relevance of comorbid MetSyn on depression in adults of mixed ages have yielded varied results: Sagud and colleagues (2013) found no association between MetSyn and treatment resistance, while Vogelzangs et al (2014) and Woo et al (2016) associated treatment resistance with metabolic dysfunction but did not evaluate MetSyn specifically.…”

Section: Introductionmentioning

confidence: 99%

Effect of Metabolic Syndrome on Late‐Life Depression: Associations with Disease Severity and Treatment Resistance

Mulvahill

Nicol

Dixon

et al. 2017

J American Geriatrics Society

View full text Add to dashboard Cite

Background Metabolic syndrome (MetSyn) is the co-occurrence of obesity with metabolic derangements. Prior research implicates MetSyn in prolonging the course of depression in older adults, but MetSyn’s effect on antidepressant response is unknown in this population. Objectives To determine if MetSyn and related metabolic dyscrasias are associated with decreased remission from depression among older adults treated pharmacologically for depression. Design Secondary analysis of a randomized controlled trial. Participants Adults 60 years and older with major depressive disorder (MDD, n=435) recruited from three academic medical centers in North America. Intervention Open-label, protocolized treatment with venlafaxine extended-release for twelve or more weeks. Main Measures Time-to-remission from depression, with remission defined as Montgomery-Åsberg Depression Rating Scale (MADRS) score ≤ 10 at last two visits. Key Results Of 435 participants (mean age 69.1 years), 222 (51%) met criteria for MetSyn at baseline; MetSyn was associated with greater severity (MADRS score) and chronicity of depression at baseline. Remission was achieved in 182 participants (42%). In the unadjusted analysis, MetSyn was associated with prolonged time-to-remission (hazard ratio for remission 0.71, 95% CI 0.52 – 0.95) but this relationship was not significant in the adjusted model; greater number of MetSyn components and lower HDL cholesterol had similar effects. Only diastolic blood pressure (DBP) was a significant predictor of time-to-remission before and after adjustment, with higher DBP predicting prolonged time-to-remission. Insulin sensitivity did not predict time-to-remission. Conclusion The presence of MetSyn in depressed, older adults is associated with greater symptom severity and chronicity of depression in our sample, which appear to account for the decreased antidepressant response observed among those with MetSyn. Additionally, our preliminary finding relating higher DBP with decreased antidepressant response bears further examination and replication.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Metabolic Syndrome on Late‐Life Depression: Associations with Disease Severity and Treatment Resistance

Mulvahill

Nicol

Dixon

et al. 2017

J American Geriatrics Society

View full text Add to dashboard Cite

show abstract

“…Our major hypothesis was inspired by Duarte et al who documented the association between SOD2 Val16Ala genetic polymorphism and rosuvastatin response in hypercholesterolaemia . Rosuvastatin response in this pathology could be modulated by the in Ala‐ or Val/Val‐carrier patients.…”

Section: Discussionmentioning

confidence: 99%

“…Our major hypothesis was inspired by Duarte et al 23 who documented the association between SOD2 Val16Ala genetic polymorphism and rosuvastatin response in hypercholesterolaemia. 35 Rosuvastatin response in this pathology could be modulated by the in Ala-or Val/Val-carrier patients. Likewise, several clinical and preclinical observations suggest that MDD also involves an inflammatory dimension, which could be influenced by antidepressant treatment.…”

mentioning

confidence: 97%

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

Tayeb

Becquemont

El‐Asmar

et al. 2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Two thirds of patients suffering from a major depressive episode (MDE) do not reach a complete response with antidepressant drugs. This lack of response is due to several factors, including genetic determinants. Since major depressive disorder is associated with inflammatory and oxidative stress abnormalities, the metabolism of superoxide anions might be involved in non‐response to antidepressant drugs. Superoxide anions are metabolized by manganese‐dependent superoxide dismutase (SOD2) in the mitochondria. A functional genetic polymorphism (SOD2, rs4880), responsible of a 40% reduction in enzyme activity, is associated with anti‐inflammatory response of rosuvastatin. We investigated the association of ala‐allele of SOD2 rs4880 and both antidepressant efficacy and inflammatory parameters in patients treated for a MDE with antidepressant drugs. The Hamilton Depression Rating Scale (HDRS) score and levels of plasma CRP and inflammatory cytokines were assessed at baseline, one month (M1), 3 months (M3) and 6 months (M6) after antidepressant treatment. They were compared according to SOD2 genetic polymorphism. Of the 484 patients studied, 361 (74.6%) carried the ala‐allele (Ala group), 123 (25.4%) of them had Val/Val genotype (Val/Val group). No significant difference was observed between the Ala and Val/Val groups neither for baseline clinical characteristics, nor for HDRS scores, response/remission rates, plasma CRP and cytokine levels throughout the study. The rs4880 SOD2 genetic polymorphism was not associated with the clinical response and cytokines levels after antidepressant treatment. These data suggest that SOD2 is not a major genetic determinant of antidepressant response. Other genes of the oxidative stress pathways should be explored in further studies.

show abstract

“…A 1-year naturalistic study by Woo et al. ( 26 ) found that the presence of obesity in patients with MDD was associated with a decreased treatment response to antidepressants (OR = 1.55). Males with concurrent metabolic problems ( i.e.…”

Section: Obesitymentioning

confidence: 99%

Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness

et al. 2020

View full text Add to dashboard Cite

People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and major depressive disorder, have a higher mortality rate and shortened life expectancy. This is mainly attributable to physical diseases, particularly cardiovascular diseases (CVDs). Important risk factors for CVDs are obesity and other metabolic abnormalities, which are especially prevalent in people with SMI. Several factors contribute to this increased risk, including unhealthy lifestyles. Psychotropic medication independently further increases this risk. In this review we want to examine the relationship between obesity and other components of the metabolic syndrome and psychotropic medication in people with SMI.

show abstract

Association of treatment response with obesity and other metabolic risk factors in adults with depressive disorders: Results from a National Depression Cohort study in Korea (the CRESCEND study)

Cited by 18 publications

References 60 publications

Effect of Metabolic Syndrome on Late‐Life Depression: Associations with Disease Severity and Treatment Resistance

Effect of Metabolic Syndrome on Late‐Life Depression: Associations with Disease Severity and Treatment Resistance

SOD2 genetic polymorphism (rs4880) has no impact on 6‐month response to antidepressant treatment and inflammatory biomarkers in depressed patients

Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness

Contact Info

Product

Resources

About